News | Taiwan Blood Services Foundation ESG

The launch ceremony was jointly attended by Dr. Te-Yuan Chen (1st from left), Executive Director of the Taiwan Rheumatology Association; Dr. Tien-Tsai Cheng (2nd from left), President of the Taiwan Rheumatology Association; Dr. Po-Sheng Ko (3rd from left), President of the Taiwan Society of Hematology; Dr. Sheng-Mao Hou (3rd from right), Chairman of the Taiwan Blood Services Foundation; Mr. Tsung-Hsi Wang (2nd from right), CEO of the Taiwan Blood Services Foundation; and Mr. Ying-Yi Liu (1st from right), General Manager of CSL Behring Taiwan Ltd. Their participation highlights the strong support from all sectors for the “National Blood for National Use” policy.

On August 9–10, 2025 the “Immunology Disease Management Joint Symposium” was held at the Courtyard by Marriott Taipei Downtown. The event was jointly organized by CSL Behring Taiwan (the distributor of the national blood products), the Taiwan Society of Hematology, and the Taiwan Rheumatology Association.

During the symposium, a concurrent event was held to celebrate the “Second-Generation National Blood Product Yikang” Immunoglobulin Privigen TW and its one-year anniversary on the market. Chairman Sheng-Mao Hou and CEO Tsung-Hsi Wang of the Taiwan Blood Services Foundation were invited to attend. In his speech at the launch ceremony, Chairman Hou expressed his hope that medical professionals would continue to support the “National Blood for National Use” policy, to validate the clinical value of national blood products through evidence-based applications, and to further promote social participation and blood donation awareness. This ensures that more patients will receive the best possible care through our collective efforts. He sincerely invited participants to become advocates and guardians of “National Blood for National Use,” jointly safeguarding the sustainability and safety of Taiwan’s healthcare system.